Find information on thousands of medical conditions and prescription drugs.

Keratoconjunctivitis sicca

Keratoconjunctivitis sicca (KCS), also called keratitis sicca, xerophthalmia, dry eye syndrome, or simply dry eyes, is an eye disease caused by decreased tear production or increased tear film evaporation commonly found in humans and small animals. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
Kallmann syndrome
Kallmann syndrome
Kallmann syndrome
Kallmann syndrome
Kaposi sarcoma
Karsch Neugebauer syndrome
Kartagener syndrome
Kawasaki syndrome
Kearns-Sayre syndrome
Keloids
Kennedy disease
Keratoacanthoma
Keratoconjunctivitis sicca
Keratoconus
Keratomalacia
Keratosis pilaris
Kernicterus
Kikuchi disease
Klinefelter's Syndrome
Klippel Trenaunay Weber...
Klippel-Feil syndrome
Klumpke paralysis
Kluver-Bucy syndrome
Kniest dysplasia
Kocher-Debré-Semélaigne...
Kohler disease
Korsakoff's syndrome
Kostmann syndrome
Kyphosis
Seborrheic keratosis
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Keratoconjunctivitis sicca is Latin and the literal translation is "dryness of the cornea and conjunctiva". In humans, the typical symptoms are burning and a sandy-gritty eye irritation that gets worse as the day goes on. The symptoms are often caused by a loss of water from the tears that results in tears that are too "salty" or hypertonic. The best treatment strategies are designed to rehydrate the tears and eye surface, and include hypotonic, electrolyte-balanced tears, punctal plugs, and moist chamber spectacles. The inflammation that occurs in response to tears film hypertonicity can be suppressed by mild topical steroids or immunosuppressants such as cyclosporine, but these treatments have not been shown to help symptoms. In animals, thicker medications are often warranted because most owners cannot reapply eye medicines more than 3-4 times a day.

Keratoconjunctivitis sicca usually occurs in people who are otherwise healthy. It is more common with older age, because tear production decreases with age. In rare cases, it can be associated with rheumatoid arthritis, lupus erythematosus, Sjögren's syndrome and other similar diseases. It may also be caused by thermal or chemical burns, or (in epidemic cases) by adenoviruses. A number of studies have found that those with diabetes are more at risk for KCS .

Read more at Wikipedia.org


[List your site here Free!]


Emerging Trends in Dry Eye Management
From Optometric Management, 4/1/05 by Lebow, Kenneth

Clinical pearls for the diagnosis, treatment and management of this ocular surface disease.

Diagnosingary eve disease is a complex and multitafactorial process. In an attempt to makes process a little easier this article will review some or the emerging trends in the diagnosis, treatment and management of the dry eye patietint.

How it all begins

The National Eye Institute (NEI) Workshop classifies dry eye into the following etiologies:

* tear deficient (Sjögrens and nonSjögrens disease)

* evaporative (oil-deficient lid-related, contact lens- or surface changeinduced).

However, additional factors (aging, external environmental changes, systemic medications, ocular surgery, chronic blepharitis or meibomianitis) can further complicate the diagnosis. Inflammation and tear film hyperosmolarity are also major components that experts associate with this disorder. In some contact lens situations, otherwise asymptomatic contact lens wearers may report dryness only when wearing their lenses. Other obstacles get in our way, as I'll explain.

Hurdles to anticipate

A significant problem with dry eye is that patient signs and symptoms often don't correlate. It's not unusual for one patient to report significant symptoms such as burning, scratchiness and stinging, but to not demonstrate clinical signs of conjunctival hyperemia, reduced tear break-up time (TBUT), corneal or conjunctival staining. At the other extreme, some patients may claim that they're virtually symptom-free, yet they manifest significant corneal and conjunctival involvement. Patients may also show both signs and symptoms but these may not be consistent from patient to patient.

Moreover, researchers have associated pro-inflammatory mediators such as cytokines and leukotrines with an inflammatory component of dry eye. Because of this significant dichotomy between signs and symptoms, practitioners frequently diagnose dry eye solely on the basis of patient-reported symptoms in response to dry eye questionnaires. And, when a patient reports dry eye symptoms in the absence of clinically demonstrable signs, more often than not, a practitioner will consider him to have a dry eye problem.

Bucking tradition

One of the more significant emerging trends in our understanding of dry eye disease calls into question the traditional description of the tear film as distinct monolayers: mucin, aqueous and lipid.

The established view of dry eye disease links mucin deficiency with non-wetting and surface damage, aqueous deficiency with keratoconjunctivitis sicca or "true" dry eye and meibum deficiency with evaporative dry eye. A more contemporary model of the human tear film describes the tears as being in aqueous phase throughout their entire thickness with varying concentrations of different types of mucins located in different areas.

For example, mucins 1,4 and 16 (MUCl, -4 and -16) are transmembrane mucins associated with the corneal and conjunctival epithelial layer and help develop the glycocalyx. MUC5AC is a gel-forming mucin released from goblet cells that's typically found in the substance of the aqueous of the tears while MUC7 from the lacrimal gland is a more soluble type of mucin. Clearly, these different mucins play diverse roles in the stabilization of the tear film, reduction of evaporative effects and the protection of the ocular surface. Check out "Know Your Mucins" below for a simple overview.

Another concept gaining acceptance in the industry and among practitioners is that the tears are like a living ocean comprised of the ocular surface, glycocalyx and three tear zones. The eyelids are the equivalent of the land surrounding the ocean of tears and can create motion that affects the stability of the tear film. Deficiency in any component of the ocular surface environment can lead to a compromised tear film, which in turn causes cellular damage. In addition to mucins and the tear film, the role of glycocalyx in ocular surface disease (OSD) is an important factor in dry eye patients.

Glycocalyx and OSD

Scientists describe glycocalyx as a cotton candy-like structure that the epithelial surface cells produce to trap mucins to the microvilli on the ocular surface. They also associate disruption of the glycocalyx with tear film instability. Figure 1 provides a theoretical example of glycocalyx.

A damaged glycocalyx exposes the epithelial cell, resulting in a loss of microvilli. Loss of transmembrane mucins such as MUCl, -4 and -16 ultimately expose the underlying, inherently hydrophobic corneal surface, which causes destabilization of the tear film with the development of dry spots as evaluated with vital dyes. Once exposed, the corneal surface loses the protection of an intact tear film. Then it's up to us to determine the severity of a patient's condition.

Making the call

The McMonnies Index, Candees and the Ocular Surface Dis ease Index (OSDI) are dry eye questionnaires, but practitioners don't just use them to identify dry eye patients; they've incorporated them to evaluate the success of therapeutic intervention providing a readily quantifiable assessment of patient response to therapy.

Protecting the ocular surface

The goal of all dry eye therapies is to maintain a protected ocular surface. Blinking is one mechanism that helps spread the tear film over the ocular surface and re-establish its integrity. However, an open eye exposes itself to various atmospheric factors that exert an additional evaporative force on the tear film, reducing its volume and increasing the exposure of the ocular surface to damage and desiccation.

A protected ocular surface will exist as long as the tear film remains stable. Once tear film break up occurs (before the next blink re-distributes the tear film) the ocular surface is at risk of corneal damage. Repeated exposure to reduced TBUT between blinks can result in corneal staining and patient reports of ocular discomfort.

The Ocular Protection Index (OPI) represents another emerging trend in managing dry eye disease and helps to quantify this phenomenon. An OPI of greater than 1.0 represents a tear-protected ocular surface. Conversely, an OPI of less than 1.0 depicts an unprotected ocular surface with exacerbated signs and symptoms.

For a review of treatment strategies geared toward dry eye disease, see "Dry Eye Treatment Tactics" beginning on page 35.

Put some thought into it

Although dry eye disease is a chronic condition that can defy treatment, it requires a logical therapeutic approach. Our ultimate goals in treating dry eye disease should include regeneration of epithelial cells, reductions in signs and symptoms of dry eye and the establishment of a healthy ocular surface.

References available on request.

BY KENNETH LEBOW, O.D., EA.A.O.

Virginia Beach, Virg.

Dr. Lebow is a contact lens specialist as well as an author, lecturer, clinical researcher and industry consultant.

Copyright Boucher Communications, Inc. Apr 2005
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Keratoconjunctivitis sicca
Home Contact Resources Exchange Links ebay